Matinas BioPharma Holdings, Inc. (MTNB) Stock Forecast
MTNB analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 2 analysts
- Price target
- $30.00 average of analyst targets
- Upside to target
- +1,165.8% from the latest close
- Next earnings
- November 9, 2026
- 52-week range
- $2.37 – $24.75
MTNB analyst ratings
2 analystsNumber of analysts at each rating.
MTNB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MTNB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$1.50 | — | — |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MTNB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | — | — |
MTNB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MTNB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MTNB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MTNB beat in 6 of 7.
What analysts expect from MTNB
2 analysts cover Matinas BioPharma; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.00, 1,165.8% above the latest close of $2.37. For 2026 the average estimate is $0.00 per share. Matinas BioPharma beat the EPS estimate in 6 of the last 7 quarters.
Related: MTNB income statement, MTNB key metrics, MTNB chart. See the MTNB stock overview for the latest quote and news.
MTNB forecast FAQ
What is Matinas BioPharma's price target?
The average analyst price target for Matinas BioPharma is $30.00, 1,165.8% above the latest close of $2.37.
Is Matinas BioPharma a buy, hold or sell?
Of 2 analysts covering Matinas BioPharma, 0 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
When does Matinas BioPharma report earnings?
Matinas BioPharma is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
Does Matinas BioPharma usually beat earnings estimates?
Matinas BioPharma reported EPS at or above the analyst estimate in 6 of the last 7 quarters.